S'abonner

Predictive markers for humoral influenza vaccine response in patients with common variable immunodeficiency - 06/12/18

Doi : 10.1016/j.jaci.2018.02.052 
Ann Gardulf, RN, PhD a, b, , Hassan Abolhassani, MD, PhD a, b, g, Rolf Gustafson, MD, PhD c, Lars E. Eriksson, RN, MSc, PhD d, e, f, Lennart Hammarström, MD, PhD a, b
a Division of Clinical Immunology and Transfusion Medicine, Department of Laboratory Medicine, Karolinska Institutet, Stockholm, Sweden 
d Department of Learning, Informatics, Management and Ethics, Karolinska Institutet, Stockholm, Sweden 
b Jeffrey Modell Diagnostic and Research Center for Primary Immunodeficiencies, Karolinska University Hospital, Campus Flemingsberg, Stockholm, Sweden 
f Department of Infectious Diseases, Karolinska University Hospital, Stockholm, Sweden 
c Immunodeficiency Unit, Department of Infectious Diseases, Karolinska University Hospital, Stockholm, Sweden 
e Division of Nursing, School of Health Sciences, City, University of London, London, United Kingdom 
g Research Center for Immunodeficiencies, Pediatrics Center of Excellence, Children's Medical Center, Tehran University of Medical Sciences, Tehran, Iran 

Corresponding author: Ann Gardulf, RN, PhD, Department of Laboratory Medicine, Division of Clinical Immunology and Transfusion Medicine, Alfred Nobels allé 8, Karolinska Institutet, Huddinge, SE-141 86 Stockholm, Sweden.Department of Laboratory MedicineDivision of Clinical Immunology and Transfusion MedicineAlfred Nobels allé 8, Karolinska InstitutetHuddingeStockholmSE-141 86Sweden

Abstract

Background

A subgroup of patients with common variable immunodeficiencies (CVIDs) responds to vaccination. The aim of this study was to try to identify predictive markers for those with a humoral immune response after influenza vaccination.

Methods

Forty-eight patients with CVID (29 female and 19 male patients; mean age, 57.7 years) were vaccinated with the A(H1N1) influenza vaccine Pandemrix (GlaxoSmithKline, Wavre, Belgium) and boosted after 1 month. Blood samples were collected before each vaccination and 2 months later. Patients with a 4-fold titer increase in results on the hemagglutinin inhibition test (≥1:40) were considered responders and compared with nonresponders for clinical, immunologic, and genetic markers.

Results

Eight (16.7%) patients responded to the vaccination. A significantly higher proportion of the responders, who showed a EUROclass SmBTrnorm21norm profile (P = .03) with a post–germinal center B-cell pattern (P = .04) in blood, experienced enteropathies (P = .04) compared with nonresponders. On the other hand, bronchiectasis was found exclusively among nonresponders (n = 7), as was autoimmune cytopenia (n = 5). Nonresponders with a EUROclass SmBTrnorm21low profile (P = .02) had a significantly greater prevalence of progressive antibody deficiency (P = .048) and, at diagnosis, a higher mean serum IgM level (P = .03), lower mean serum IgG1 level (P = .007), expansion of absolute counts of cytotoxic CD8+ T cells (P = .033), and increased proportion of memory CD8+ T cells (P = .044) in blood. CVID-associated HLA markers were not detected in responders (P = .03).

Conclusion

About one fifth of the patients with CVIDs achieved protective antibody levels after A(H1N1) vaccination and selected clinical, and immunologic markers were identified that might predict a positive outcome of influenza vaccination. Patients with CVID should be offered vaccination also against seasonal influenza because of the potential severity of the infection and risk for bacterial complications.

Le texte complet de cet article est disponible en PDF.

Key words : Common variable immunodeficiency, specific antibody deficiency, vaccination, influenza, pandemic influenza, immune response, A(H1N1), Pandemrix

Abbreviations used : CVID, HA, PID, TACI


Plan


 Supported by the Jeffrey Modell Foundation, New York, NY, and the Swedish Research Council, Stockholm, Sweden.
 Disclosure of potential conflict of interest: The authors declare that they have no relevant conflicts of interest.


© 2018  Publié par Elsevier Masson SAS.
Ajouter à ma bibliothèque Retirer de ma bibliothèque Imprimer
Export

    Export citations

  • Fichier

  • Contenu

Vol 142 - N° 6

P. 1922 - décembre 2018 Retour au numéro
Article précédent Article précédent
  • Role of human forkhead box P3 in early thymic maturation and peripheral T-cell homeostasis
  • Francesca R. Santoni de Sio, Laura Passerini, Silvia Restelli, Maria Maddalena Valente, Aleksandar Pramov, Maria Elena Maccari, Francesca Sanvito, Maria Grazia Roncarolo, Matthew Porteus, Rosa Bacchetta
| Article suivant Article suivant
  • Phenotype, penetrance, and treatment of 133 cytotoxic T-lymphocyte antigen 4–insufficient subjects
  • Charlotte Schwab, Annemarie Gabrysch, Peter Olbrich, Virginia Patiño, Klaus Warnatz, Daniel Wolff, Akihiro Hoshino, Masao Kobayashi, Kohsuke Imai, Masatoshi Takagi, Ingunn Dybedal, Jamanda A. Haddock, David M. Sansom, Jose M. Lucena, Maximilian Seidl, Annette Schmitt-Graeff, Veronika Reiser, Florian Emmerich, Natalie Frede, Alla Bulashevska, Ulrich Salzer, Desirée Schubert, Seiichi Hayakawa, Satoshi Okada, Maria Kanariou, Zeynep Yesim Kucuk, Hugo Chapdelaine, Lenka Petruzelkova, Zdenek Sumnik, Anna Sediva, Mary Slatter, Peter D. Arkwright, Andrew Cant, Hanns-Martin Lorenz, Thomas Giese, Vassilios Lougaris, Alessandro Plebani, Christina Price, Kathleen E. Sullivan, Michel Moutschen, Jiri Litzman, Tomas Freiberger, Frank L. van de Veerdonk, Mike Recher, Michael H. Albert, Fabian Hauck, Suranjith Seneviratne, Jana Pachlopnik Schmid, Antonios Kolios, Gary Unglik, Christian Klemann, Carsten Speckmann, Stephan Ehl, Alan Leichtner, Richard Blumberg, Andre Franke, Scott Snapper, Sebastian Zeissig, Charlotte Cunningham-Rundles, Lisa Giulino-Roth, Olivier Elemento, Gregor Dückers, Tim Niehues, Eva Fronkova, Veronika Kanderová, Craig D. Platt, Janet Chou, Talal A. Chatila, Raif Geha, Elizabeth McDermott, Su Bunn, Monika Kurzai, Ansgar Schulz, Laia Alsina, Ferran Casals, Angela Deyà-Martinez, Sophie Hambleton, Hirokazu Kanegane, Kjetil Taskén, Olaf Neth, Bodo Grimbacher

Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.

Déjà abonné à cette revue ?

Mon compte


Plateformes Elsevier Masson

Déclaration CNIL

EM-CONSULTE.COM est déclaré à la CNIL, déclaration n° 1286925.

En application de la loi nº78-17 du 6 janvier 1978 relative à l'informatique, aux fichiers et aux libertés, vous disposez des droits d'opposition (art.26 de la loi), d'accès (art.34 à 38 de la loi), et de rectification (art.36 de la loi) des données vous concernant. Ainsi, vous pouvez exiger que soient rectifiées, complétées, clarifiées, mises à jour ou effacées les informations vous concernant qui sont inexactes, incomplètes, équivoques, périmées ou dont la collecte ou l'utilisation ou la conservation est interdite.
Les informations personnelles concernant les visiteurs de notre site, y compris leur identité, sont confidentielles.
Le responsable du site s'engage sur l'honneur à respecter les conditions légales de confidentialité applicables en France et à ne pas divulguer ces informations à des tiers.


Tout le contenu de ce site: Copyright © 2025 Elsevier, ses concédants de licence et ses contributeurs. Tout les droits sont réservés, y compris ceux relatifs à l'exploration de textes et de données, a la formation en IA et aux technologies similaires. Pour tout contenu en libre accès, les conditions de licence Creative Commons s'appliquent.